Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CONMED Corporation’s (NYSE: CNMD) U.S. Securities and Exchange Commission filings, with AI-powered tools to help interpret the information. CONMED files a variety of reports under the Securities Exchange Act of 1934, and its common stock is registered on the New York Stock Exchange under the symbol CNMD, as noted in multiple Form 8-K filings.
For this medical equipment company in the surgical and medical instrument manufacturing industry, SEC filings are a primary source for understanding its financial condition, operating performance and strategic actions. Current reports on Form 8-K disclose events such as quarterly and year-to-date financial results, portfolio optimization steps, changes in directors and executive officers, dividend declarations, and share repurchase authorizations. For example, recent 8-K filings describe the announcement of second and third quarter financial results, the intent to exit gastroenterology product lines, the appointment of a new independent director, the resignation of a director, the declaration of a quarterly cash dividend, and a planned transition of the Chief Financial Officer.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when accessed through this page, contain detailed financial statements, segment information for orthopedic and general surgery, and discussions of items that are later referenced in non-GAAP reconciliations, such as product rationalization costs, operational optimization consulting fees, executive transition costs, legal matters, contingent consideration fair value adjustments, restructuring and related costs, and other specified items. These filings also provide context for guidance on revenue and adjusted diluted earnings per share that CONMED discusses in its press releases and investor presentations.
In addition to giving direct access to the underlying documents, this page uses AI to summarize key points from lengthy filings, highlight important sections, and surface items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Users can review CONMED’s historical and current SEC disclosures here, along with AI-generated insights that explain the significance of each filing in clear language.
CONMED Corporation filed a Form 3 reporting that Kim Kelderman became a director on 09/08/2025. The filing shows 0 shares of common stock beneficially owned as of the event date and lists the reporting relationship as Director. The Form 3 was executed by power of attorney on 09/09/2025. This is an initial Section 16 filing required when an insider becomes a director; it discloses current ownership (none reported) and does not list any derivative holdings or other indirect ownership.
Fuller & Thaler Asset Management, Inc. filed a Schedule 13G reporting beneficial ownership of 1,740,630.07 shares of Conmed Corp common stock, representing 5.63% of the class. The filer reports sole voting power for 1,714,377.07 shares and sole dispositive power for 1,740,630.07 shares, with no shared voting or dispositive power disclosed.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Fuller & Thaler acts as investment adviser to the underlying accounts that own the shares.
Todd W. Garner, Executive Vice President & CFO of CONMED Corp (CNMD), reported a single insider sale. On 08/07/2025 he sold 598 shares of CONMED common stock at $52.45 per share, and the Form 4 reports he beneficially owns 0 shares following the transaction. The Form 4 was signed via power of attorney on 08/08/2025.
CONMED Corporation announced its Board declared a quarterly cash dividend of $0.20 per share. The dividend was declared on August 7, 2025 and is payable on October 3, 2025 to shareholders of record as of September 15, 2025. This is a cash distribution to owners of the company and represents a direct return of capital to shareholders for the quarter.
The current 8-K contains only the dividend declaration and payment details; it does not disclose earnings, changes to dividend policy, or other financial metrics. Investors seeking additional context on the company’s payout history or cash position will need to consult recent periodic reports or investor presentations.